Black Hawk Acquisition Corporation (BKHA)
Healthcare › Biological Products, (No Diagnostic Substances)
Price History
Feb 9, 2026 — Apr 4, 2026Investment Snapshot
- P/E of 21.7 — elevated valuation multiple
- Piotroski F-Score 3/9 — signs of financial weakness
- Loss-making — negative ROE of -88.2%
Black Hawk Acquisition Corporation (BKHA) is a Healthcare company operating in Biological Products, (No Diagnostic Substances), listed on the NASDAQ , with a market capitalisation of $48 million . Key value metrics: P/E ratio 21.7, Piotroski F-Score 3 out of 9 .
Value Score
Key Metrics
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Black Hawk Acquisition Corporation — Fundamental Analysis Summary
Black Hawk Acquisition Corporation (BKHA) trades at a trailing P/E of 21.7x — 14% below the Healthcare sector average of 25.3x.
On financial health, BKHA shows a weak Piotroski F-Score of 3/9, a signal of deteriorating financial health, and negative return on equity of -88.2% (sector average: -19.8%).
StockPik's composite Value Score for BKHA is 35/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
BKHA shows earnings declining at 31%.